Sun Brighter After US Import Ban Worries Recede
This article was originally published in PharmAsia News
Executive Summary
Analysts say that the US Food and Drug Administration's warning letter to India's biggest drug-maker, Sun Pharma, has helped allay investor concerns about the possibility of major delays in making the company's Halol plant compliant with the regulator's standards.